Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys

Documenti analoghi

• In vitro combined haemostatic efficacy of emicizumab and extended half‐life factor VIII compounds
  di: Laurie Josset, et al.
  Pubblicazione: (2025)
• Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B
  di: Brigitte Tardy‐Poncet, et al.
  Pubblicazione: (2024)
• Genetic Analysis of a Family With Hereditary Factor V Deficiency Induced by Compound Heterozygous Variants (IVS24+3A>T and p.Asp2222Gly)
  di: Ben Huang, et al.
  Pubblicazione: (2026)
• Association between cognitive impairment and functional limitations in everyday life in patients with haemophilia in Hong Kong
  di: Yin Ting Cheung, et al.
  Pubblicazione: (2024)
• Managing Acute Coronary Syndrome and Surgical Revascularization in a Patient With Severe Haemophilia A on Emicizumab: Lessons Learned From a Clinical Case
  di: Paige Muir, et al.
  Pubblicazione: (2026)